Search Results - "Kikkert, W J"

Optimal duration of dual antiplatelet therapy for coronary artery disease by Kikkert, W. J., Damman, P.

“…The optimal duration of dual antiplatelet therapy (DAPT) for stable coronary artery disease and acute coronary syndrome is a complex decision. We review…”
Get full text

Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes by Claessen, Bimmer E P M, Kikkert, Wouter J, Engstrom, Annemarie E, Hoebers, Loes P C, Damman, Peter, Vis, Marije M, Koch, Karel T, Baan, Jr, Jan, Meuwissen, Martijn, van der Schaaf, René J, de Winter, Robbert J, Tijssen, Jan G P, Piek, Jan J, Henriques, José P S

“…The general population is gradually ageing in the western world. Therefore, the number of octogenarians undergoing primary percutaneous coronary intervention…”
Get more information

Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system by Claessen, B E, Stone, G W, Smits, P C, Kedhi, E, Kikkert, W J, Piek, J J, Henriques, J P S

“…Treatment options for coronary revascularisation include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). In the 'synergy…”
Get full text

Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals by Kikkert, W. J., Piek, J. J., de Winter, R. J., Peters, R. J., Henriques, J. P. S.

“…To assess current Dutch antithrombotic treatment strategies for acute coronary syndrome (ACS) in light of the current European Society of Cardiology (ESC)…”
Get full text

Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients by Azzahhafi, J, Van Den Broek, W A, Chan Pin Yin, D R P P, Van Der Sangen, N M R, Sivanesan, S, Van Schaik, R, Henriques, J P, Kikkert, W J, Ten Berg, J M

Get full text

The impact of body mass on cardiovascular outcomes in patients with acute coronary syndrome by Van Den Broek, W W A, Azzahhafi, J, Chan Pin Yin, D R P P, Van Der Sangen, N M R, Henriques, J P S, Kikkert, W J, Ten Berg, J M

Get full text

The risk-treatment paradox in acute coronary syndrome patients: insights from the FORCE-ACS registry by Azzahhafi, J, Van Der Sangen, N M R, Chan Pin Yin, D R P P, Simao Henriques, J P, Kikkert, W J, Ten Berg, J M

Get full text

External validation of the Global Registry of Acute Coronary Events (GRACE) risk score: insights from the FORCE-ACS registry by Van Der Sangen, N M R, Azzahhafi, J, Chan Pin Yin, D R P P, Ten Berg, J M, Henriques, J P S, Kikkert, W J

Get full text

Risk score guided dual antiplatelet therapy duration in patients with acute coronary syndrome: insights from the FORCE-ACS registry by Chan Pin Yin, D, Van Der Sangen, N M R, Azzahhafi, J, Van Den Broek, W, Bor, W L, Peper, J, Sivanesan, S, Tjon Joe Gin, R M, Nicastia, D, Langerveld, J, Vlachojannis, G, Appelman, Y, Henriques, J P S, Kikkert, W J, Ten Berg, J

Get full text

Radial crossover and unsuccessful radial access during coronary angiography or percutaneous coronary intervention: insights from the FORCE-ACS registry by Van Der Sangen, N M R, Azzahhafi, J, Chan Pin Yin, D R P P, Torunogullari, E E, Ten Berg, J M, Henriques, J P S, Kikkert, W J

Get full text

Conservative management in a contemporary cohort of patients with acute coronary syndrome: results from the FORCE-ACS registry by Chan Pin Yin, D, Azzahhafi, J, Rayhi, S, Peper, J, Van Der Sangen, N M R, Tjon Joe Gin, R M, Nicastia, D M, Walhout, R, Langerveld, J, Bor, W L, Vos, G J A, Henriques, J P S, Kikkert, W J, Ten Berg, J M

Get full text

Prognostic value of access site and non-access site bleeding in ST-segment elevation myocardial infarction by Kikkert, W. J., Delewi, R., Vis, M. M., Baan, J., Koch, K. T., De Winter, R. J., Peters, R. J., Piek, J. J., Tijssen, J. G. P., Henriques, J. P.

Get full text

Associations of major bleeding and recurrent myocardial infarction with the incidence and timing of mortality in patients with ST-segment elevation myocardial infarction by Kikkert, W. J., Zwinderman, A. H., Vis, M. M., Baan, J., Koch, K. T., Peters, R. J., De Winter, R. J., Piek, J. J., Tijssen, J. G. P., Henriques, J. P.

Get full text

Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction by Claessen, Bimmer E P M, Hoebers, Loes P, van der Schaaf, René J, Kikkert, Wouter J, Engstrom, Annemarie E, Vis, Marije M, Baan, Jr, Jan, Koch, Karel T, Meuwissen, Martijn, van Royen, Niels, de Winter, Robbert J, Tijssen, Jan G P, Piek, Jan J, Henriques, José P S

“…Recently, a chronic total occlusion (CTO) in a non-infarct-related artery (non-IRA) and not multivessel disease (MVD) alone was identified as an independent…”
Get more information

Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI by Kikkert, W J, van Nes, S H, Lieve, K V V, Dangas, G D, van Straalen, J, Vis, M, Baan, Jr, J, Koch, K T, de Winter, R J, Piek, J J, Tijssen, J G P, Henriques, J P

“…Unfractionated heparin is the most commonly used anticoagulant in ST-elevation myocardial infarction (STEMI) and its effect can be monitored with activated…”
Get more information

Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals by Kikkert, W. J., Piek, J. J., de Winter, R. J., Peters, R. J., Henriques, J. P. S.

Get full text

Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?: A meta-analysis of a first-generation vs. a second-generation drug-eluting stent system by Claessen, B. E., Stone, G. W., Smits, P. C., Kedhi, E., Kikkert, W. J., Piek, J. J., Henriques, J. P. S.

Get full text